Special Issue

Updates on Gene Expression Analyses in Anti-Cancer Drug Research

Message from the Guest Editors

We are pleased to announce a Special Issue dedicated to the latest advancements in gene expression analyses within the context of anti-cancer drug research. As the understanding of cancer biology deepens, gene expression profiling has become increasingly pivotal in identifying novel therapeutic targets, predicting drug responses, and overcoming resistance mechanisms. This Special Issue aims to showcase cutting-edge research that leverages gene expression analyses to enhance the development and efficacy of anti-cancer therapies. We invite researchers to submit original research articles and reviews that provide new insights into how gene expression data can be utilized to innovate and refine cancer treatment strategies. This issue will serve as a comprehensive resource for scientists and clinicians interested in integrating molecular biology and pharmacology to target and treat cancer more effectively.

Guest Editors

Dr. Ana Luísa De Sousa-Coelho

- 1. Escola Superior de Saúde, Universidade do Algarve (ESSUAlg), Campus de Gambelas, 8005-139 Faro, Portugal
- 2. Algarve Biomedical Centre Research Institute (ABC-RI), Campus de Gambelas, 8005-139 Faro, Portugal

Dr. Mónica Fernandes

- Algarve Biomedical Center-Research Institute (ABC-RI), University of Algarve Campus Gambelas, 8005-139 Faro, Portugal
- 2. Escola Superior de Saúde, Universidade do Algarve (ESSUAIg), Campus de Gambelas, 8005-139 Faro, Portugal

Deadline for manuscript submissions

closed (30 July 2025)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



mdpi.com/si/214786

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

